Dabigatran: how the drug company withheld important analyses

BMJ. 2014 Jul 23;349:g4670. doi: 10.1136/bmj.g4670.
No abstract available

MeSH terms

  • Antithrombins / administration & dosage
  • Antithrombins / adverse effects*
  • Antithrombins / blood*
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / adverse effects*
  • Benzimidazoles / blood*
  • Dabigatran
  • Dose-Response Relationship, Drug
  • Drug Approval
  • Drug Industry / legislation & jurisprudence
  • Drug Monitoring*
  • Europe
  • Hemorrhage / chemically induced*
  • Hemorrhage / prevention & control
  • Humans
  • United States
  • United States Food and Drug Administration
  • beta-Alanine / administration & dosage
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / blood

Substances

  • Antithrombins
  • Benzimidazoles
  • beta-Alanine
  • Dabigatran